bioRxivCancer Biology
Preclinical exploration of the DNA Damage Response pathway using the interactive neuroblastoma cell line explorer CLEAN.
J. Gabre, P. Merseburger, A. Claeys, J. Siaw, S.-L. Bekaert, F. Speleman, B. Hallberg, R. Palmer, J. Van den Eynden
Abstract
Neuroblastoma (NB) is the most common cancer in infancy with an urgent need for more efficient targeted therapies. The development of novel (combinatorial) treatment strategies relies on extensive explorations of signaling perturbations in neuroblastoma cell lines, using RNA-Seq or other high throughput technologies (e.g., phosphoproteomics). This typically requires dedicated bioinformatics support, which is not always available. Additionally, while data from published studies are highly valuable and raw data (e.g., fastq files) are nowadays released in public repositories, data processing is time-consuming and again difficult without bioinformatics support. To facilitate NB research, more user-friendly and immediately accessible platforms are needed to explore newly generated as well as existing high throughput data. To make this possible, we developed an interactive data centralization and visualization web application, called CLEAN (the Cell Line Explorer web Application of Neuroblastoma data; https://ccgg.ugent.be/shiny/clean/). By focusing on the regulation of the DNA damage response, a therapeutic target of major interest in neuroblastoma, we demonstrate how CLEAN can be used to gain novel mechanistic insights and identify putative drug targets in neuroblastoma.
- organism: human
- assay: bulk RNA-seq
- assay: proteomics
- research focus: cell type annotation
- research focus: differential expression
- research focus: drug response / drug discovery
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Histotripsy-initiated immune response synergizes with chemotherapy in a neuroblastoma murine model
Natalia L. Antonides-Jensen, Muskan Singh, … Sonia L. Hernandez·CancersPeer-reviewed·Apr 15, 2026
- DNA Damage Response Deficiency Enhances Neuroblastoma Progression and Sensitivity to Combination PARP and ATR Inhibition
Madeline N. Hayes, Sarah Cohen‐Gogo, … Meredith S. Irwin·Cell ReportsPeer-reviewed·Apr 1, 2025
- An integrated single-cell RNA-seq map of human neuroblastoma tumors and preclinical models uncovers divergent mesenchymal-like gene expression programs.
R. H. Chapple, X. Liu, … P. Geeleher·bioRxiv·Apr 13, 2023
- Cell lineage as a predictor of immune response in neuroblastoma
S. Sengupta, S. Das, … R. E. George·bioRxiv·Jan 29, 2021
- Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy
J. Wienke, L. L. Visser, … J. J Molenaar·bioRxiv·Jul 15, 2022
- A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma
A. K. Weiner, A. B. Radaoui, … S. J. Diskin·bioRxiv·Dec 6, 2023